ArticleFuture cardiology2024
Single-center initial experience with a new pulsed-field ablation system: pulmonary vein isolation lesions and beyond.
Article in Future cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07035288 (Electroanatomical Mapping Versus Fluoroscopy Based Pulmonary Vein Isolation by Means of PulseSelect Catheter in Patients With Atrial Fibrillation), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Electroanatomical Mapping Versus Fluoroscopy Based Pulmonary Vein Isolation by Means of PulseSelect Catheter in Patients With Atrial Fibrillation
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulsed-field ablation (PFA) is a newer energy delivery method, an alternative to thermal lesion, allowing for safe and durable pulmonary vein isolation in the context of atrial fibrillation ablation. Graded tissue sensitivity allows for specifically targeting atrial cardiomyocytes, rendering collateral damage to nearby nerves and vessels unlikely. In the present rapid communication, we report on our center's initial experience with a novel PFA platform and describe the ways in which it can be used targeting sites beyond PV ostia and antra, in the context of atrial fibrillation/flutter/tachycardia ablation, alone or in conjunction with a mainstream 3-dimensional electroanatomical mapping system (3D-EAM). More specifically, the exploratory application of PFA in the vicinity of pacemaker/defibrillator leads may prove of particular significance for clinical practice, given the frequent need to isolate the superior vena cava in patients bearing a transvenous cardiac rhythm management device.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.